Skip to main content

Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Quantification of 15 Organic Impurities of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Combined Dosage Form

A Correction to this article was published on 22 July 2019

This article has been updated

Abstract

A novel, simple, robust and rapid reversed-phased high performance liquid chromatographic method has been developed for the separation and quantitative determination of the 15 organic impurities of olmesartan medoxomil, amlodipine and hydrochlorothiazide in combined dosage forms. Successful separation of five impurities of olmesartan medoxomil, six impurities of amlodipine and four impurities of hydrochlorothiazide, and degradation products formed under stress conditions, was achieved on Inertsil ODS-3 (100 × 4.6 mm, 3.0 μm) column, using gradient elution. The mobile phase A contains 0.0 2 M phosphate buffer (pH 3.3) and acetonitrile in a ratio of (95:05, v/v%) and mobile phase B contains 0.02 M phosphate buffer (pH 3.3), acetonitrile and methanol in a ratio of (20:60:20, v/v/v%). Flow rate monitored at 1.8 mL min−1, and UV detection carried out at 237 nm. During forced degradation studies, the effect of acid, base, oxidation, UV light and temperature was investigated, showing good resolution between the peaks corresponding to process and degradation-related impurities. The performance of the method was validated according to the present ICH guidelines for specificity, linearity, accuracy, precision, ruggedness and robustness. To the best of our knowledge, this is the first research paper which presents a simple and rapid HPLC method, which separates all impurities of olmesartan medoxomil, amlodipine and hydrochlorothiazide in combined dosage forms.

Graphical Abstract

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Change history

  • 22 July 2019

    The authors would like to call the reader’s attention to the following change in the corresponding authorship to Priti J. Mehta and Pritesh R. Desai’s affiliation.

References

  1. 1.

    O'Neil MJ (2006) The merck index: an encyclopedia of chemicals, drugs, and biologicals, vol 14, pp 83, 827, 1178

  2. 2.

    Brousil JA, Burke JM (2003) Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 25(4):1041–1055

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Püchler K, Nussberger J, Laeis P, Witte PU, Brunner HR (1997) Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 15(12):1809–1812

    Article  PubMed  Google Scholar 

  4. 4.

    Martindale KP (2005) The extra pharmacopoeia. The Complete Drug Reference 34(3):2005

    Google Scholar 

  5. 5.

    Mason RP, Marche P, Hintze TH (2003) Novel vascular biology of third-generation l-type calcium channel antagonists: ancillary actions of amlodipine. Arter Thromb Vasc Biol 23(12):2155–2163

    Article  CAS  Google Scholar 

  6. 6.

    Stepien O, Zhang Y, Zhu D, Marche P (2002) Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J Hypertens 20(1):95–102

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Barrett WE, Rutledge RA, Sheppard H, Plummer AJ (1959) The pharmacology of hydrochlorothiazide (Esidrix™), a new, orally effective sulfonamide diuretic. Toxicol Appl Pharmacol 1(4):333–349

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D (1998) The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13(7):1682–1685

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Solini A, García-Donaire JA, Ruilope LM (2012) Combination therapy in hypertension. Curr Cardiovasc Risk Rep 6(4):291–298

    Article  Google Scholar 

  10. 10.

    Rockville MD (2017) United States pharmacopeia and national formulary (USP 41-NF 36). United States Pharmacopeial Convention. https://online.uspnf.com/uspnf. Accessed 18 Jan 2018

  11. 11.

    Celebier M, Altinoz S (2007) Determination of olmesartan medoxomil in tablets by UV–Vis spectrophotometry. Pharmazie 62(6):419–422

    CAS  PubMed  Google Scholar 

  12. 12.

    Sridhar K, Sastry CSP, Reddy MN, Sankar DG, Srinivas KR (1997) Spectrophotometric determination of amlodipine besylate in pure forms and tablets. Anal Lett 30(1):121–133

    Article  CAS  Google Scholar 

  13. 13.

    Merey HA, Ramadan NK, Diab SS, Moustafa AA (2014) Spectrophotometric methods for simultaneous determination of ternary mixture of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide. Spectrochim Acta A 125:138–146

    Article  CAS  Google Scholar 

  14. 14.

    Bhusari KP, Khedekar PB, Dhole S, Banode VS (2009) Derivative and Q-analysis spectrophotometric methods for estimation of hydrochlorothiazide and olmesartan medoxomil in tablets. Indian J Pharm Sci 71(5):505

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Sharma T, Si SC, Gowrishankar D (2010) Difference spectrophotometric method for the determination of Olmesartan medoxomil in tablets. J Pharm Res 3(7):1553–1555

    CAS  Google Scholar 

  16. 16.

    Patel J, Kevin G, Patel A, Raval M, Sheth N (2011) Development of the UV spectrophotometric method of Olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies. Pharm Methods 2(1):36

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Mehulkumar P, Ramesh V, Kumar VV, Srinivas R, Diwan PV (2009) Simultaneous spectroscopic estimation of amlodipine besylate and Olmesartan medoximil in tablet dosage form. Asian J Res Chem 2(2):127–130

    CAS  Google Scholar 

  18. 18.

    Farouk M, EL-Aziz OA, Hemdanb A, Shehata M (2011) Simple novel spectrophotometric and spectrofluorimetric methods for determination of some antihypertensive Drugs. J Am Sci 7:300–312

    Google Scholar 

  19. 19.

    Darwish HW, Bakheit AH, Darwish IA (2012) New spectrofluorimetric methods for the simultaneous determination of olmesartan medoxamil and amlodipine besylate in their combined tablets. Dig J Nanomater Bios 7:1599–1608

    Google Scholar 

  20. 20.

    Bahrami GH, Mirzaeei SH (2004) Simple and rapid HPLC method for determination of amlodipine in human serum with fluorescence detection and its use in pharmacokinetic studies. J Pharm Biomed Anal 36(1):163–168

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Tatar S, Atmaca S (2001) Determination of amlodipine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 758(2):305–310

    Article  CAS  PubMed  Google Scholar 

  22. 22.

    Shah NJ, Suhagia BN, Shah RR, Patel NM (2007) Development and validation of a simultaneous HPTLC method for the estimation of olmesartan medoxomil and hydrochlorothiazide in tablet dosage form. Indian J Pharm Sci 69(6):834

    Article  CAS  Google Scholar 

  23. 23.

    Solanki TB, Shah PA, Patel KG (2014) Central composite design for validation of HPTLC method for simultaneous estimation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in tablets. Indian J Pharm Sci 76(3):179

    PubMed  PubMed Central  Google Scholar 

  24. 24.

    Kamble AY, Mahadik MV, Khatal LD, Dhaneshwar SR (2010) Validated HPLC and HPTLC method for simultaneous quantitation of amlodipine besylate and olmesartan medoxomil in bulk drug and formulation. Anal Lett 43(2):251–258

    Article  CAS  Google Scholar 

  25. 25.

    Qi W, Zhao Q, Jiang J, Hu P (2013) Simultaneous determination of olmesartan and amlodipine in human plasma and urine by ultra performance liquid chromatography tandem mass spectrometry. J Chromatogr B 938:27–34

    Article  CAS  Google Scholar 

  26. 26.

    Tiwari RN, Shah N, Bhalani V, Mahajan A (2015) LC, MSn and LC–MS/MS studies for the characterization of degradation products of amlodipine. J Pharmaceut Anal 5(1):33–42

    CAS  Google Scholar 

  27. 27.

    Murakami T, Konno H, Fukutsu N, Onodera M, Kawasaki T, Kusu F (2008) Identification of a degradation product in stressed tablets of Olmesartan medoxomil by the complementary use of HPLC hyphenated techniques. J Pharm Biomed Anal 47(3):553–559

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Liu D, Jiang J, Wang P, Feng S, Hu P (2010) Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 878(9–10):743–748

    Article  Google Scholar 

  29. 29.

    Rahman MM, Khan SB, Faisal M, Rub MA, Al-Youbi AO, Asiri AM (2012) Electrochemical determination of olmesartan medoxomil using hydrothermally prepared nanoparticles composed SnO2–Co3O4 nanocubes in tablet dosage forms. Talanta 99:924–931

    Article  CAS  PubMed  Google Scholar 

  30. 30.

    Shimooka K, Sawada Y, Tatematsu H (1989) Analysis of amlodipine in serum by a sensitive high-performance liquid chromatographic method with amperometric detection. J Pharm Biomed Anal 7(11):1267–1272

    Article  CAS  PubMed  Google Scholar 

  31. 31.

    Josefsson M, Zackrisson AL, Norlander B (1995) Sensitive high-performance liquid chromatographic analysis of amlodipine in human plasma with amperometric detection and a single-step solid-phase sample preparation. J Chromatogr B Biomed Sci Appl 672(2):310–313

    Article  CAS  Google Scholar 

  32. 32.

    Jain PS, Patel MK, Gorle AP, Chaudhari AJ, Surana SJ (2012) Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form. J Chromatogr Sci 50(8):680–687

    Article  CAS  PubMed  Google Scholar 

  33. 33.

    Rao JR, Rajput MP, Yadav SS, Mulla TS, Bharekar VV (2011) Simultaneous quantitation of olmesartan medoxomil, Amlodipine besylate and hydrochlorothiazide in pharmaceutical dosage form by using HPLC. Int J PharmTech Res 3(3):1435–1440

    CAS  Google Scholar 

  34. 34.

    Kumar KK, Rao CK, Madhusudan G, Mukkanti K (2012) Rapid simultaneous determination of olmesartan—amlodipine and hydrochlorothiazide in combined pharmaceutical dosage form by stability-indicating ultra performance liquid chromatography. Am J Analyt Chem 3(01):50

    Article  CAS  Google Scholar 

  35. 35.

    Kurbanoglu S, Gumustas M, Ozkan SA (2013) Simultaneous estimation and validation of some binary mixtures of antihypertensive drugs by RP-LC methods using two new generation silica columns. J Pharm Biomed Anal 72:198–201

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    Hamrapurkar PD, Gadapayale KK (2013) Optimization and validation of RP-HPLC stability indicating method for determination of olmesartan medoxomil and its degraded product. Int J Appl Sci Eng 11(2):137–147

    Google Scholar 

  37. 37.

    Zarghi A, Foroutan SM, Shafaati A, Khoddam A (2005) Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. Farmaco 60(9):789–792

    Article  CAS  PubMed  Google Scholar 

  38. 38.

    Jain PS, Patel MK, Gorle AP, Chaudhari AJ, Surana SJ (2012) Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form. J Chromatogr Sci 50(8):680–687

    Article  CAS  PubMed  Google Scholar 

  39. 39.

    ICH guideline (Q2A) (R1) (2005) Validation of analytical procedures: text and methodology. http://www.ich.org. Accessed 18 Jan 2019

Download references

Acknowledgements

The authors of the current work wish to acknowledge the management of Zydus Cadila Healthcare Limited for supporting this work, and are grateful to their colleagues from Analytical Research and Development Laboratories.

Funding

This study was not funded by any grants.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Pritesh R. Desai.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict regarding publication of this paper.

Ethical approval

This article does not contain any studies with human participants/animals performed by any authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Desai, P.R., Mehta, P.J. & Chokshi, A.B. Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Quantification of 15 Organic Impurities of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Combined Dosage Form. Chromatographia 82, 819–833 (2019). https://doi.org/10.1007/s10337-019-03718-9

Download citation

Keywords

  • High-performance liquid chromatography
  • Impurity
  • Method validation
  • Olmesartan medoxomil
  • Amlodipine besylate
  • Hydrochlorothiazide